BELLEROPHONProject reference: 601783
Funded under :
comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN
Total cost:EUR 7 105 812,8
EU contribution:EUR 5 498 829
Coordinated in:United Kingdom
Topic(s):HEALTH.2013.2.3.1-1 - Drugs and vaccines for infections that have developed or are at the risk of developing significant anti-microbial resistance
Call for proposal:FP7-HEALTH-2013-INNOVATION-2See other projects for this call
Funding scheme:CP-FP - Small or medium-scale focused research project
"Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals.
Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to which antibiotic resistance is developing.
To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a Phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains.
The project will rely on 4 key components:
i) a recently discovered and highly conserved T-cell inducing antigen individually capable of eliciting substantial protection in mouse models;
(ii) a secreted toxin antigen, antibodies against which reduce mortality (Hla);
(iii) an innovative, proprietary and potent pro-immunogenic series of tags (IMX313 series) which can be fused to the antigens;
(iv) the use of viral vectors, including an innovative and proprietary adenoviral vector (ChAdOx1) and/or new ways to use viral vectors to generate protective immunity (MVA mixed with proteins).
i) identify the most protective method of combining these components in a manufacturable and clinically deployable manner;
ii) manufacture and perform initial human studies of the vaccine;
iii) identify additional antigens which might further increase the efficacy of the initial product.
Our approach will contribute clinical safety and immunogenicity data for a novel vaccine strategy targeting one of the key bacterial pathogens in man. It will pave the way for rapid progression to phase II studies, and thence to larger phase II/III studies aiming to reduce infection."
EU contribution: EUR 2 022 378
University Offices, Wellington Square
OX1 2JD OXFORD
Tel.: +44 1865 289800
Fax: +44 1865 289801
EU contribution: EUR 2 505 885
RUE SAINT ROCH 5/7
Tel.: +33 6 79 82 92 70
Fax: +33 4 74 26 15 78
EU contribution: EUR 452 000
ROUTE DE LA CORNICHE 4
Tel.: +41 795612794
EU contribution: EUR 518 566
IM NEUERHEIMER FELD 307